News
Pathos AI signs two cancer deals with Alphamab and AZ
Pathos AI has grown its oncology pipeline by licensing a bispecific ADC from Alphamab for $125m and partnering a breast cancer drug from AstraZeneca.
News
Curium strikes $8bn deal to buy radiopharma rival Lantheus
Two players in the radiopharma sector, Curium and Lantheus, have agreed to merge and create an end-to-end player in diagnostics and therapeutics.
Oncology
Key lessons from EHA 2026: Translating evidence into impact
Across four days in Sweden, EHA 2026 offered a clear view of the future of blood cancer care.
News
Datroway joins Trodelvy for frontline TNBC in the EU
AstraZeneca and Daiichi Sankyo's Datroway enters the first-line triple-negative breast cancer market in the EU, taking on Gilead's Trodelvy.
News
Adcomm backs Replimune melanoma drug, despite data concern
Replimune's RP1 immunotherapy for melanoma clears advisory committee vote by 10 to three, despite FDA concerns about the design of the IGNYTE study.
News
Views & Analysis
Deep Dive
Editor's Picks
Editor's Picks
